Can better approaches for suppressing gastric acid improve outcomes in patients with Helicobacter pylori infection?

In this episode, Dr. Zhiqiang Song from the Department of Gastroenterology, Peking University Third Hospital, China, explains how potassium-competitive acid blockers (P-CABs)—therapeutics capable of more sustained gastric acid suppression compared to proton pump inhibitors (PPI)—may represent the future of standard care for H. pylori infection.

A nationwide Phase III trial comparing P-CABs to PPIs in standard treatment regimens for H. pylori infection is the focus of an article by Dr. Song and collaborators published in the Chinese Medical Journal. The article is titled, “Tegoprazan-based versus esomeprazole-based triple therapy plus bismuth for first-line Helicobacter pylori eradication: A nationwide, multicenter, double-blind, double-dummy, randomized controlled trial.”

Guest: Dr. Zhiqiang Song

Host: John L

Summary:

We explore the potential benefits of using potassium-competitive acid blockers as an alternative to proton pump inhibitors in the standard eradication therapy for Helicobacter pylori.

What makes some stroke cases more severe than others, and what can be done to improve outcomes? In this episode of Medspeak by the Chinese Medical Journal, Dr. Wu Simiao and Dr. Craig S. Anderson discuss their recent study on severe acute ischemic stroke.

Drawing on data from over 4,000 patients in China, they explore why some people with stroke decline quickly, which treatments show the most promise, and how hospitals can better support recovery in patients at high-risk.

This podcast, based on the study titled “Clinical course, causes of worsening, and outcomes of severe ischemic stroke: A prospective multicenter cohort study,” aims to delve into deep discussions regarding the underexplored domain of stroke, to improve the quality of life.

Host: John L

Guests: Dr. Wu Simiao and Dr. Craig S. Anderson

Summary:

In this podcast, we explore the progression of severe ischemic stroke, the impact of key risk factors, and how therapies like endovascular treatment and intravenous thrombolysis affect patient outcomes.

Will the humanized monoclonal antibody CM310 transform treatment outcomes for patients with atopic dermatitis?

In this episode, we speak with Dr. Jianzhong Zhang, Professor at Peking University People’s Hospital, who introduces a breakthrough drug for atopic dermatitis called CM310 and discusses its potential to improve the quality of life for patients living with this chronic skin condition.

In 2024, Dr. Zhang and his collaborators published the results of a pivotal clinical trial evaluating the efficacy and safety of CM310. The article is titled, “Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial.”

Guest: Dr. Jianzhong Zhang
Host: John L

Summary:

We explore the potential of a monoclonal antibody drug—named CM310—for treating atopic dermatitis, focusing on the results of a clinical trial conducted in China and published in the Chinese Medical Journal.